AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

User:

Stage 1: History of Subacute B-Symptoms, Anemia & Massive Splenomegaly (Timestamp: 2 Months Prior to Admission)
A 51-year-old woman (residing in Delhi NCR, homemaker, past history of treated follicular thyroid carcinoma S/P thyroidectomy & radioiodine, migraine, depression/anxiety) presents with a 2-month history of fatigue, night sweats, left-upper-quadrant fullness, early satiety, pedal edema, and exertional dyspnea.
HPI:
- 1 Month Ago (1st Admission): Examination revealed massive splenomegaly extending to the pelvic brim (30 cm x 10 cm on CT) and ascites. Transfused 2 units PRBCs. HIV negative.
- Day 5 of 1st Admission: Prolonged aPTT noted that failed to correct on 1:1 mixing study. Transfused 3 units FFP + 2 units PRBCs. Bone marrow biopsy performed.
- Current Readmission: Recurrent fever (38.6°C), night sweats, progressive fatigue, and worsening pedal edema requiring transfer.

Resident:

Hello, Chief Resident here.

Key Findings:
A 51-year-old female from Delhi NCR presenting with subacute B-symptoms, severe anemia, ascites, massive splenomegaly (30 cm), and a prolonged aPTT failing to correct on 1:1 mixing study, indicating a circulating anticoagulant/inhibitor.

Differential Diagnoses & Reasoning:
1. Splenic Lymphoproliferative Disorder (e.g., SMZL/DLBCL) or Primary Myelofibrosis (45%): Primary suspect given massive splenomegaly, B-symptoms, ascites, and paraneoplastic autoimmune phenomena (circulating inhibitor).
2. Visceral Leishmaniasis / Kala-azar (35%): Endemic in India; classically presents with massive splenomegaly, persistent fever, cytopenias, and hypergammaglobulinemia causing coagulation study interference.
3. Disseminated Tuberculosis or HLH (15%): Infectious/inflammatory driver fitting prolonged fever, cytopenias, splenomegaly, and severe dysregulation.
4. Metastatic Follicular Thyroid Carcinoma (5%): Known history, though isolated massive splenic metastasis is extremely rare.

Recommended Prioritized Tests:
1. Bone Marrow Aspirate & Biopsy Results: Flow cytometry, IHC, cytogenetics, and smears for LD bodies.
2. rK39 Immunochromatographic Test / Leishmania PCR.
3. Lupus Anticoagulant Panel & Specific Factor Assays (Factor VIII/IX/XI) to characterize the inhibitor.
4. Ascitic Fluid Analysis: Cell count, SAAG, cytology, and GeneXpert MTB/Rif.
5. HLH Workup: Serum ferritin, triglycerides, and fibrinogen levels.

Attending:

Hello Attending Consultant here

Critique: Solid prioritization of BM and rK39, but underweights inhibitor characterization and ignores tropical co-infections endemic to Delhi NCR. Mixing-study failure needs immediate LA/factor workup before attributing to hypergammaglobulinemia. Ascites SAAG/cytology is essential; HLH labs are premature without ferritin trigger threshold.

Top 3 DDx:
1. Visceral leishmaniasis (with secondary inhibitor)
2. Splenic marginal-zone lymphoma
3. Primary myelofibrosis / prefibrotic PMF

Specific points:
1. Expedite LA panel + FVIII/FIX assays + Bethesda titer.
2. Add Leishmania PCR on BM/aspirate, not just rK39.
3. Quantify JAK2/CALR/MPL and BCR-ABL on BM.
4. CT chest/abdomen for nodal disease + PET if lymphoma likely.
5. Repeat aPTT post-FFP to assess inhibitor kinetics.
6. TB QuantiFERON + ascitic GeneXpert.
7. Hold empiric steroids until infection excluded.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Visceral leishmaniasis (kala-azar). Months of fever and night sweats, massive splenomegaly, anemia, hypoalbuminemic ascites/edema, and a lupus-type inhibitor (described with chronic VL) cohere elegantly

Round 2

User:

Stage 2: Physical Exam & Severe Coombs-Negative Hemolytic Anemia (Timestamp: Admission / Day 1)
Physical Exam: Anxious, febrile (38.3°C), HR 105 bpm, BP 110/68 mmHg, RR 18/min, SpO2 96% on room air. Mild scleral icterus. No peripheral lymphadenopathy. Abdomen: Soft, non-tender; massive firm non-tender splenomegaly extending below the pelvic brim. Legs: Bilateral pitting pedal edema.
Initial Laboratory Workup:
- CBC & Reticulocytes: WBC 4,600/µL (67% neutrophils, 24% lymphocytes, 6% monocytes), Hemoglobin 7.2 g/dL (Hct 21.4%, MCV 89 fL, nadir 5.7 g/dL), Platelets 156,000/µL. Reticulocytes 9.2% (marked reticulocytosis!). Smear: 3+ Anisocytosis, 1+ Polychromasia, occasional Schistocytes.
- Hemolysis & Paraprotein Biomarkers: Total Bilirubin 2.4 mg/dL (Direct 0.7 mg/dL = indirect hyperbilirubinemia), LDH 1,540 U/L, Haptoglobin undetectable (<6 mg/dL). AST 44 U/L, ALT 19 U/L. Direct Coombs test & cold agglutinins negative.
- Serum Protein Electrophoresis: IgM kappa monoclonal paraprotein (0.12 g/dL) with severe immunoparesis (IgG 268 mg/dL, IgA 7 mg/dL).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Coexistence of massive splenomegaly, Coombs-negative severe hemolysis (reticulocytes 9.2%, LDH 1540 U/L, undetectable haptoglobin, schistocytes), an IgM kappa monoclonal paraprotein (0.12 g/dL) with profound immunoparesis, and a prolonged uncorrected aPTT.

Differential Diagnoses & Reasoning:
1. Splenic Lymphoproliferative Disorder (e.g., SMZL or WM/Lymphoplasmacytic Lymphoma) (50%): Explains the IgM paraprotein, immunoparesis, massive splenomegaly, B-symptoms, and secondary Coombs-negative/hypersplenic hemolysis.
2. Visceral Leishmaniasis (30%): Geographically highly relevant; classically causes massive splenomegaly, B-symptoms, secondary hemolysis, and reactive monoclonal/polyclonal gammopathies with autoantibodies.
3. Primary Myelofibrosis (15%): Presents with massive splenomegaly, B-symptoms, and extramedullary hematopoiesis with fragmented red cells.
4. Thrombotic Microangiopathy / Atypical AIHA (5%): Drug/paraneoplastic-induced microangiopathic hemolysis accounting for schistocytes and negative DCT.

Prioritized Next Tests:
1. Bone Marrow Aspirate/Biopsy: Histology, flow cytometry, MYD88 L265P mutation, and Leishmania PCR/smear.
2. Serum Free Light Chain (SFLC) Assay & peripheral blood flow cytometry.
3. ADAMTS13 Activity & peripheral smear re-evaluation for TMA.
4. rK39 Rapid Diagnostic Test / Leishmania PCR.
5. Lupus Anticoagulant & Factor VIII/IX Activity Assays.

Attending:

Hello Attending Consultant here

Critique: Overweights WM/SMZL given tiny IgM (0.12 g/dL) insufficient for hyperviscosity or primary hemolysis; under-explores parasite-driven cold-agglutinin-negative hemolysis and inhibitor. ADAMTS13 premature without more schistocytes/thrombocytopenia. BM remains pivotal but must include explicit LD-body stains + MYD88 only if LPL still viable.

Top 3 DDx:
1. Visceral leishmaniasis (secondary IgM, inhibitor, hypersplenism)
2. Splenic marginal-zone lymphoma
3. Prefibrotic myelofibrosis with extramedullary hemolysis

Specific points:
1. Urgent BM: Giemsa for amastigotes, Leishmania PCR, flow, JAK2/CALR.
2. Quantify cold-agglutinin titer + thermal amplitude despite neg screen.
3. Full LA panel + specific factor assays/Bethesda.
4. rK39 + blood/BM Leishmania PCR in parallel.
5. SFLC ratio + urine immunofixation for clone significance.
6. Haptoglobin/LDH serials post-transfusion; avoid empiric steroids.
7. PET-CT only after infection excluded.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Visceral leishmaniasis. It elegantly explains the massive splenomegaly, chronic B-symptoms, secondary hypersplenic hemolysis, polyclonal/monoclonal immune dysregulation with severe immunoparesis, and the lupus-like inhibitor causing the uncorrected aPTT. The schistocytes point to a microangiopathic component from severe hypersplenism rather than a primary TMA, especially given normal platelets.

Top differentials:
1. Splenic marginal-zone lymphoma — fits splenomegaly + IgM, but the tiny 0.12 g/dL paraprotein and profound hemolysis out of proportion argue against primary clone.
2. Primary myelofibrosis — massive spleen + B-symptoms, yet no teardrop cells/leukoerythroblastosis or marrow fibrosis clues yet.
3. Lymphoplasmacytic lymphoma/Waldenström — IgM + immunoparesis, but paraprotein too small and hemolysis atypically Coombs-negative.
4. Atypical TMA — schistocytes + hemolysis, but normal platelets and absence of renal dysfunction make it less likely.

Key pivot: The uncorrected aPTT (circulating inhibitor) + Coombs-negative hemolysis strongly shift the case from a pure clonal B-cell disorder toward an infectious/paraneoplastic mimic such as VL.

Most important next move: Immediate bone marrow Giemsa stain for Leishman-Donovan bodies plus Leishmania PCR, simultaneously with rK39 serology and lupus anticoagulant/factor assays. This single test can unify splenomegaly, hemolysis, paraprotein, and coagulopathy in an endemic region.

Teaching pearl: In a patient from a VL-endemic area presenting with massive splenomegaly, pancytopenia/hemolysis, monoclonal gammopathy, and acquired inhibitor, exclude kala-azar before labeling the process lymphoma—VL is the great hematologic masquerader.

Round 3

User:

Stage 3: Mixing Study, Lupus Anticoagulant & Abdominal CT Imaging (Timestamp: Hospital Days 1-2)
Coagulation Studies & Autoantibodies:
- PT 14.7s (INR 1.3), aPTT 63.9s (severely prolonged!). Fibrinogen 499 mg/dL, D-Dimer 2,101 ng/mL.
- Mixing Study: 1:1 mixing with normal plasma failed to correct the prolonged aPTT (persisted >60s).
- Autoantibody Panel: Lupus Anticoagulant POSITIVE; IgM Anticardiolipin Autoantibodies >150 MPL units (strongly positive!).
Contrast CT Imaging: Massive homogeneous splenomegaly (30 cm in length) extending into the pelvic brim, with enlarged lymph nodes in the splenic hilum and para-aortic region. No focal splenic lesions.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Massive 30 cm homogeneous splenomegaly with hilar/para-aortic lymphadenopathy, severe Coombs-negative hemolysis, small IgM kappa paraprotein, and high-titer Antiphospholipid Antibodies (Lupus Anticoagulant positive, IgM Anticardiolipin >150 MPL) driving the uncorrected aPTT prolongation.

Differential Diagnoses & Reasoning:
1. Visceral Leishmaniasis with secondary Antiphospholipid Syndrome (55%): Endemic trigger in Delhi NCR capable of producing massive splenomegaly, reactive IgM paraproteinemia, severe Coombs-negative hemolysis, and secondary high-titer antiphospholipid antibodies.
2. Splenic Lymphoproliferative Disorder (e.g., SMZL or DLBCL) (30%): Homogeneous massive splenomegaly, lymphadenopathy, and IgM paraprotein with paraneoplastic autoantibody production.
3. Primary Myelofibrosis (10%): Explains massive splenomegaly, extramedullary disease, and secondary autoantibodies, though marked aCL titers are atypical.
4. Primary Antiphospholipid Syndrome / SLE (5%): Explains severe hemolysis and high-titer aCL/LA, but a 30 cm spleen is extremely rare.

Prioritized Next Steps:
1. Bone Marrow Aspirate & Biopsy: Giemsa stain for LD bodies, Leishmania PCR, flow cytometry, and JAK2/MYD88 mutation analysis.
2. rK39 Rapid Diagnostic Test & Peripheral Blood Leishmania PCR.
3. Factor Assays (VIII, IX, XI, XII): Exclude true factor deficiencies before invasive procedures.
4. Autoimmune Panel: ANA, anti-dsDNA, C3/C4 levels.

Attending:

Hello Attending Consultant here

Critique: Appropriately elevates VL with secondary APS, but overcalls primary APS/SLE (spleen size incompatible) and under-emphasizes need for immediate factor assays before any procedure. BM plan solid; add explicit amastigote stains. ANA panel low-yield without other SLE features.

Top 3 DDx:
1. Visceral leishmaniasis (secondary APS + IgM clone)
2. Splenic marginal-zone lymphoma (paraneoplastic aPL)
3. Lymphoplasmacytic lymphoma / WM variant

Specific points:
1. Urgent BM Giemsa + Leishmania PCR/rK39.
2. Factor VIII/IX/XI assays + Bethesda before biopsy.
3. MYD88 L265P + BRAF on BM/flow.
4. Serial aPL titers; avoid anticoagulation absent thrombosis.
5. PET-CT for nodal FDG avidity post-infection exclusion.
6. Hold steroids/IVIG until VL ruled out.
7. Quantify cryoglobulins given IgM + aCL.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Visceral leishmaniasis with secondary antiphospholipid antibodies and an IgM paraprotein. Endemic kala-azar explains the massive homogeneous splenomegaly, B-symptoms, hypersplenic Coombs-negative hemolysis, high-titer aCL/LA, and small reactive IgM clone.

Top differentials:
1. Splenic marginal-zone lymphoma – fits splenomegaly, nodes, IgM, and paraneoplastic aPL, but profound immunoparesis and hemolysis exceed the tiny paraprotein.
2. Primary myelofibrosis – massive spleen + hemolysis, yet lacks teardrop/leukoerythroblastosis and strongly positive aPL is unusual.
3. Primary APS/SLE – explains aPL + hemolysis, but a 30 cm spleen and IgM paraprotein are atypical.

Key pivot: Extremely high-titer antiphospholipid antibodies with an uncorrected mixing study strongly point to a secondary (infectious or lymphoproliferative) driver rather than primary APS.

Next move: Bone marrow Giemsa for Leishman-Donovan bodies + Leishmania PCR and rK39, performed only after confirming adequate factor VIII/IX/XI levels. Flow cytometry/MYD88 can run in parallel.

Teaching pearl: In endemic regions, visceral leishmaniasis frequently produces high-titer antiphospholipid antibodies, lupus anticoagulant, and monoclonal gammopathy—mimicking APS or lymphoma—so always exclude kala-azar before labeling the process autoimmune or malignant.

Round 4

User:

Stage 4: Bone Marrow Biopsy, Flow Cytometry & Pathologic Unification (Timestamp: Hospital Days 3-5)
Bone Marrow Histopathology & Flow Cytometry:
- Bone Marrow Histopathology: Nodular and intrasinusoidal aggregates of small B-lymphocytes comprising ~10% of marrow cellularity (excluding Hairy-Cell Leukemia, which shows diffuse interstitial infiltration).
- Flow Cytometry (Marrow & Blood): Clonal B-cell population expressing kappa light chain, CD19+, but CD5-, CD23-, CD10-, and CD103-. Smear: Occasional mildly enlarged lymphocytes with non-circumferential villous cytoplasmic projections ("villous lymphocytes").
- Unifying Diagnosis: Splenic Marginal-Zone Lymphoma (SMZL) presenting with massive splenomegaly, IgM kappa paraproteinemia, Coombs-negative autoimmune hemolytic anemia (driven by warm IgM autoantibodies / splenic sequestration), and secondary Antiphospholipid Syndrome (Lupus Anticoagulant).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Bone marrow histopathology and flow cytometry establish intrasinusoidal CD19+ CD5- CD10- CD23- CD103- B-cell infiltration (~10%) with circulating villous lymphocytes, confirming Splenic Marginal-Zone Lymphoma (SMZL) complicated by secondary Antiphospholipid Syndrome (LA positive, high-titer aCL), IgM kappa paraproteinemia, and severe Coombs-negative hemolysis.

Differential Diagnoses & Reasoning:
1. Splenic Marginal-Zone Lymphoma (SMZL) with Secondary APS & AIHA (95%): Pathologically confirmed by characteristic intrasinusoidal infiltration, immunophenotype, villous lymphocytes, and massive splenomegaly.
2. Lymphoplasmacytic Lymphoma / Waldenström Variant (3%): Overlapping IgM secretion, but CD5-/CD10-/CD103- phenotype and intrasinusoidal pattern favor SMZL.
3. Visceral Leishmaniasis (Infectious Mimic) (2%): Effectively ruled out by definitive diagnostic histopathology.

Recommended Next Steps in Management:
1. Molecular & Cytogenetic Profiling: Test for NOTCH2, KLF2 mutations, and 7q deletion to assist risk stratification.
2. Hepatitis C Virus (HCV) Serology: Screen for HCV as a potentially reversible underlying driver of SMZL.
3. Serum Cryoglobulin Level: Evaluate for cryoglobulinemia secondary to the monoclonal IgM kappa paraprotein.
4. Initiate Target Therapy: Commencing Rituximab monotherapy (or chemoimmunotherapy) to treat the underlying B-cell clone and clear paraneoplastic autoantibodies.
5. Thromboprophylaxis Assessment: Monitor for thrombosis versus bleeding risk before initiating anticoagulation.

Attending:

Hello Attending Consultant here

Critique: Path confirmation of SMZL is robust (intrasinusoidal CD5-/CD103- clone + villous lymphocytes), yet plan under-addresses concurrent infection exclusion and hemolysis kinetics before rituximab. HCV screen essential; empiric therapy premature without full staging/cryoglobulin data. APS thrombosis risk needs formal Caprini scoring.

Top 3 DDx:
1. SMZL (secondary APS + IgM-driven AIHA)
2. SMZL/LPL overlap (MYD88-neg variant)
3. HCV-associated SMZL

Specific points:
1. Add MYD88 L265P + NOTCH2/KLF2/del7q on BM.
2. Urgent HCV RNA + cryoglobulins + RF.
3. PET-CT for extranodal burden pre-therapy.
4. Serial hemolysis markers; consider brief steroids only if life-threatening.
5. Hold full anticoagulation; ASA if no bleed.
6. Rituximab monotherapy first-line; defer bendamustine.
7. Repeat aPL titers 12 weeks post-treatment.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Splenic marginal-zone lymphoma (SMZL). Intrasinusoidal/nodular marrow infiltration, CD19+ CD5- CD10- CD23- CD103- immunophenotype, circulating villous lymphocytes, massive splenomegaly, IgM kappa paraprotein, Coombs-negative hemolysis, and secondary antiphospholipid antibodies unify the case.

Top differentials:
1. Lymphoplasmacytic lymphoma/WM – overlaps IgM, but intrasinusoidal pattern, villous morphology, and absent CD103 argue against it.
2. Hairy-cell leukemia variant – splenomegaly + cytopenias, yet CD103 negativity and nodular pattern exclude it.
3. Visceral leishmaniasis – strong mimic earlier, now definitively excluded by diagnostic marrow histology and flow.

Key pivot: Bone marrow biopsy showing classic SMZL histology turned the picture from an infectious/autoimmune mimic into a clonal B-cell disorder driving secondary APS and hemolysis.

Most important next move: Screen for HCV and cryoglobulins, add MYD88/NOTCH2/KLF2 testing, then initiate rituximab-based therapy after hemolysis stabilization and infection exclusion. Anticoagulation should await individualized thrombosis-bleeding assessment.

Teaching pearl: SMZL commonly masquerades as infection or primary autoimmune disease through paraproteinemia, autoimmune hemolysis, and antiphospholipid antibodies; intrasinusoidal marrow infiltration with villous lymphocytes is the diagnostic clue that should prompt early B-cell directed therapy rather than empiric steroids.

Round 5

User:

Stage 5: Therapeutic Splenectomy & Chemoimmunotherapy Outcome (Timestamp: Follow-up & Discharge)
Management & Surgical Intervention:
- Primary Treatment: Therapeutic & Diagnostic Splenectomy performed (spleen weighed 2.42 kg!). Pathological examination confirmed classic Splenic Marginal-Zone Lymphoma.
- Post-Operative Course: Complete resolution of fevers and night sweats; hemoglobin and hematocrit normalized within 6 weeks, and aPTT normalized.
- Relapse & Long-Term Outcome: At 15 Months: Recurrence of fatigue, anemia, IgM paraprotein, retroperitoneal lymphadenopathy, and DVT. Successfully treated with Rituximab + CVP (Cyclophosphamide, Vincristine, Prednisone) chemotherapy + LMWH anticoagulation, achieving complete hematologic and clinical response.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Pathologically confirmed SMZL (2.42 kg spleen) with complete resolution of secondary APS/hemolysis post-splenectomy. Relapse at 15 months with retroperitoneal lymphadenopathy, IgM paraprotein, and DVT achieved complete response following Rituximab-CVP and LMWH.

Differential Diagnoses & Reasoning:
1. Relapsed SMZL, in Complete Remission post-R-CVP (95%): Classic pattern of extra-splenic nodal recurrence post-splenectomy, demonstrating complete clinical/hematologic response to chemoimmunotherapy.
2. Histologic Transformation to DLBCL (4%): Known risk during SMZL relapse; sustained response to R-CVP makes aggressive transformation less likely.
3. Resolved Secondary Antiphospholipid Syndrome (1%): Paraneoplastic autoantibody production fully suppressed following clearance of the underlying B-cell clone.

Prioritized Next Steps in Management:
1. Serial IgM & SPEP/SFLC Monitoring: Track clonal disease burden and screen for early biochemical relapse.
2. Surveillance CT Imaging (Abdomen/Pelvis): Assess nodal response duration and monitor retroperitoneal disease.
3. Repeat Antiphospholipid Panel (LA/aCL): Determine if autoantibodies cleared to guide the duration of long-term anticoagulation.
4. Post-Splenectomy Prophylaxis & Immunoglobulins: Maintain immunizations against encapsulated pathogens and monitor IgG levels post-Rituximab.

Attending:

Hello Attending Consultant here

Critique: Surveillance plan appropriate post-R-CVP CR, but under-specifies aPL re-testing timing, anticoagulation duration (provoked DVT in active disease), and transformation vigilance. Ig monitoring good; add MRD if available. Post-splenectomy vaccines must be confirmed complete.

Top 3 DDx:
1. Relapsed SMZL now in CR (post-splenectomy + R-CVP)
2. SMZL with residual secondary APS risk
3. Occult histologic transformation (low probability given R-CVP response)

Specific points:
1. Repeat LA/aCL/β2GP1 at 12 weeks off therapy; stop LMWH if negative.
2. Confirm post-splenectomy vaccines (pneumo/mening/Hib) + boosters.
3. q3mo SPEP/SFLC + IgM for 2 yrs, then q6mo.
4. CT or PET at 6 mo to document nodal CR durability.
5. Watch for transformation (rising LDH, new B-symptoms → biopsy).
6. Pneumocystis prophylaxis if prolonged steroids/Ritux.
7. Thrombophilia panel only if unprovoked recurrence.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Splenic marginal-zone lymphoma (SMZL) with secondary antiphospholipid syndrome and warm-type autoimmune hemolytic anemia. The massive spleen, villous lymphocytes, IgM kappa paraprotein, aPL positivity, dramatic response to splenectomy, and later extra-splenic relapse treated successfully with R-CVP confirm this unified picture.

Top differentials:
1. Lymphoplasmacytic lymphoma/WM – overlaps IgM, but intrasinusoidal marrow pattern and villous morphology favor SMZL.
2. Visceral leishmaniasis – early mimic now excluded by histology and sustained response to B-cell therapy.
3. Histologic transformation to DLBCL – less likely given complete response to R-CVP.

Key pivot: Bone marrow biopsy revealing classic SMZL turned an infectious/autoimmune mimic into a clonal B-cell disorder driving paraneoplastic APS and hemolysis.

Next move: Continue surveillance IgM/SPEP and imaging; repeat antiphospholipid panel after therapy to determine whether long-term anticoagulation remains necessary; ensure complete post-splenectomy vaccination and monitor for transformation.

Teaching pearl: SMZL often presents as a paraneoplastic autoimmune syndrome (AIHA + APS + paraprotein) and can initially masquerade as infection; splenectomy is diagnostic/therapeutic early, but relapse is typically nodal and responds well to rituximab-based chemoimmunotherapy.

Top 15 Takeaways for Clinicians

  1. Classic Presentation of Splenic Marginal-Zone Lymphoma (SMZL): SMZL typically presents in older adults with massive, symptomatic splenomegaly (often extending into the pelvis), severe anemia, B-symptoms, and minimal peripheral lymphadenopathy.
  2. Intrasinusoidal Marrow Infiltration Pattern: Pathological examination of bone marrow trephine biopsy revealing nodular and intrasinusoidal aggregates of small CD20+ B-lymphocytes is highly characteristic of SMZL and excludes diffuse interstitial Hairy-Cell Leukemia.
  3. Diagnostic Peripheral Villous Lymphocytes: Peripheral blood smear demonstrating circulating small-to-medium lymphocytes with unipolar, non-circumferential villous cytoplasmic projections ("villous lymphocytes") provides a crucial morphological clue for SMZL.
  4. Pathognomonic SMZL Immunophenotype: Clonal B cells in SMZL express CD19, CD20, and kappa light chain restriction, while characteristically lacking CD5, CD10, CD23, and CD103.
  5. Paraneoplastic Autoimmune Hemolytic Anemia (AIHA): SMZL frequently triggers Coombs-negative or warm IgM-mediated autoimmune hemolytic anemia (marked reticulocytosis, elevated LDH, undetectable haptoglobin) alongside splenic sequestration.
  6. Secondary Antiphospholipid Syndrome (APS): Neoplastic B-cell clones in SMZL often secrete monoclonal IgM paraproteins with autoantibody activity, resulting in high-titer Lupus Anticoagulant and IgM Anticardiolipin antibodies causing an uncorrected prolonged aPTT.
  7. Interference of Lupus Anticoagulants on Coagulation Assays: Acquired circulating lupus anticoagulants bind phospholipid reagents in vitro, prolonging aPTT and masking intrinsic factor activities (Factors VIII, XI, XII) without true factor deficiency.
  8. Therapeutic and Diagnostic Value of Splenectomy: Splenectomy serves as both a primary diagnostic procedure and highly effective first-line therapy for SMZL, offering prompt resolution of cytopenias, B-symptoms, and autoimmune phenomena.
  9. Role of Hepatitis C Virus (HCV) Screening: All patients with marginal-zone lymphoma must be screened for Hepatitis C virus, as antiviral eradication of HCV can induce complete lymphoma regression in HCV-positive SMZL cases.
  10. Mandatory Post-Splenectomy Immunization: Prior to or immediately following splenectomy, patients must receive vaccinations against encapsulated bacterial pathogens (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b).
  11. Distinction from Visceral Leishmaniasis (Kala-Azar): In tropical and endemic regions, chronic Visceral Leishmaniasis produces massive splenomegaly, polyclonal hypergammaglobulinemia, and acquired autoantibodies, requiring bone marrow Giemsa staining and rK39 serology to exclude.
  12. Distinction from Waldenström's Macroglobulinemia (LPL): While both entities produce IgM paraproteinemia, Waldenström's typically features serum IgM >3 g/dL with prominent hyperviscosity, whereas SMZL presents with massive splenomegaly and small paraproteins (<1 g/dL).
  13. Management of Extra-Splenic Nodal Relapse: Nodal or retroperitoneal relapse post-splenectomy responds exceptionally well to Rituximab-based chemoimmunotherapy (e.g. Rituximab + CVP or Bendamustine), achieving durable complete remissions.
  14. Prognostic Molecular Markers: Somatic mutations in NOTCH2 and KLF2 or 7q deletions correlate with clinical outcomes and assist in stratifying long-term relapse risk in SMZL.
  15. Surveillance of Paraneoplastic Autoantibodies: Serial quantitative monitoring of serum IgM, SPEP, and antiphospholipid antibody titers enables detection of subclinical lymphoma recurrence before overt cytopenias manifest.